Business Description
Oryzon Genomics SA
ISIN : ES0167733015
Description
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.9 | |||||
Equity-to-Asset | 0.77 | |||||
Debt-to-Equity | 0.17 | |||||
Debt-to-EBITDA | -3.37 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 5.3 | |||||
3-Year EPS without NRI Growth Rate | 3.2 | |||||
3-Year FCF Growth Rate | 2.3 | |||||
3-Year Book Growth Rate | -2.3 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History |
---|
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.87 | |||||
Quick Ratio | 0.87 | |||||
Cash Ratio | 0.75 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.9 | |||||
Shareholder Yield % | 4.69 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -4.38 | |||||
ROA % | -3.22 | |||||
ROIC % | -2.55 | |||||
ROC (Joel Greenblatt) % | -771.53 | |||||
ROCE % | -4.78 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.47 | |||||
EV-to-EBIT | -29.43 | |||||
EV-to-EBITDA | -30.53 | |||||
EV-to-Forward-EBITDA | -18.73 | |||||
EV-to-Forward-Revenue | 12.95 | |||||
EV-to-FCF | -8.18 | |||||
Earnings Yield (Greenblatt) % | -3.41 | |||||
FCF Yield % | -12.31 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Oryzon Genomics SA Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil MXN) | |||
EPS (TTM) (MXN) | -1.086 | ||
Beta | -0.04 | ||
Volatility % | 0 | ||
14-Day RSI | 0 | ||
14-Day ATR (MXN) | 0 | ||
20-Day SMA (MXN) | 48.59 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range (MXN) | 48.59 - 48.59 | ||
Shares Outstanding (Mil) | 61.79 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Oryzon Genomics SA Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Oryzon Genomics SA Stock Events
Event | Date | Price(MXN) | ||
---|---|---|---|---|
No Event Data |
Oryzon Genomics SA Frequently Asked Questions
What is Oryzon Genomics SA(MEX:ORY)'s stock price today?
When is next earnings date of Oryzon Genomics SA(MEX:ORY)?
Does Oryzon Genomics SA(MEX:ORY) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |